Biomarker Discovery for Heterogeneous Diseases
- 1 May 2013
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 22 (5) , 747-755
Abstract
Background: Modern genomic and proteomic studies reveal that many diseases are heterogeneous, comprising multiple different subtypes. The common notion that one biomarker can be predictive for all patients may need to be replaced by an understanding that each subtype has its own set of unique biomarkers, affecting how discovery studies are designed and analyzed. Methods: We used Monte Carlo simulation to measure and compare the performance of eight selection methods with homogeneous and heterogeneous diseases using both single-stage and two-stage designs. We also applied the selection methods in an actual proteomic biomarker screening study of heterogeneous breast cancer cases. Results: Different selection methods were optimal, and more than two-fold larger sample sizes were needed for heterogeneous diseases compared with homogeneous diseases. We also found that for larger studies, two-stage designs can achieve nearly the same statistical power as single-stage designs at significantly reduced cost. Conclusions: We found that disease heterogeneity profoundly affected biomarker performance. We report sample size requirements and provide guidance on the design and analysis of biomarker discovery studies for both homogeneous and heterogeneous diseases. Impact: We have shown that studies to identify biomarkers for the early detection of heterogeneous disease require different statistical selection methods and larger sample sizes than if the disease were homogeneous. These findings provide a methodologic platform for biomarker discovery of heterogeneous diseases. Cancer Epidemiol Biomarkers Prev; 22(5); 747–55. ©2013 AACR.Keywords
All Related Versions
This publication has 35 references indexed in Scilit:
- Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancerProceedings of the National Academy of Sciences, 2011
- Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer StudyClinical Cancer Research, 2010
- Protein Microarray Signature of Autoantibody Biomarkers for the Early Detection of Breast CancerJournal of Proteome Research, 2010
- Power and sample size estimation in microarray studiesBMC Bioinformatics, 2010
- Novel Autoimmune Hepatitis-Specific Autoantigens Identified Using Protein Microarray TechnologyJournal of Proteome Research, 2009
- Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker StudiesPLOS Medicine, 2008
- Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer StudyJAMA, 2006
- Gene Expression Profiling Identifies Molecular Subtypes of Inflammatory Breast CancerCancer Research, 2005
- Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray ExperimentsStatistical Applications in Genetics and Molecular Biology, 2004
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences of the United States of America, 2003